Vincristine 2mg/2mL
| Product Overview | |
| Generic Name | Vincristine 2mg/2mL |
| Brand Name(s) | Oncovin, Vincasar |
| Form | Single-dose vial, Intravenous use only |
| Strength | 2mg/ 2mL |
| Therapeutic Class | Vinca alkaloid antineoplastic (mitotic inhibitor) |
| ATC Code | L01CA02 |
| Manufacturing & Regulatory | |
| Manufacturer | Eli Lilly, Cipla |
| Country | USA, India |
| GMP Compliance | WHO-GMP |
| DMF/CEP | Type II |
| COFEPRIS | 010.000.1768.00 |
| Free Sale Certificate | Yes |
| Logistics & Export | |
| MOQ | 10 Units |
| Shelf Life | 24 months |
| Storage | 2–8 °C |
| Incoterms | EXW/FOB/CIF negotiable |
| Lead Time | 7 to 10 Days |
| Documentation | |
| Certificate of Analysis (COA) | Yes |
| SDS | Upon Request, not publicly posted |
| CTD Summary | Full CTD dossier proprietary; available under commercial agreement/license |
Description
Indications and Usage: Vincristine is indicated for the treatment of acute lymphoblastic leukemia (ALL), Hodgkin’s and non-Hodgkin’s lymphomas, rhabdomyosarcoma, neuroblastoma, and Wilms’ tumor. It is used as part of combination chemotherapy regimens.
